We are a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing of the microbial, pDNA and mRNA modalities. Our US FDA, EMA and TGA approved site in South Australia, which was previously part of Pfizer, is staffed with a tremendously experienced technical and operations team, with most critical SME’s having an average tenure of 15+ years at the Adelaide site. Because we are not a drug developer, we only serve our client’s products and through our partnership with NovaCina, we are also able to offer our clients a highest-quality fill-and-finish solution. | BioCina is a global end-to-end Contract Development and Manufacturing Organisation (CDMO) offering clients unparalleled quality, adherence to the highest regulatory standards, and industry-leading on-time and in-full delivery, setting a new benchmark in the industry for quality and reliability. With deep expertise in small molecules, microbial, pDNA and mRNA modalities, BioCina’s comprehensive service offerings include cell line development, process development, analytical and formulation development, and cGMP clinical and commercial manufacturing. BioCina operates two state-of-the-art facilities in Adelaide, South Australia and Perth, Western Australia. The facilities boast a rich history of developing and manufacturing clinical and commercial drug substances and drug products, backed by highly experienced Subject Matter Experts (SMEs) with an average tenure of more than 10 years. BioCina maintains an elite quality record, meeting the highest international standards. The facilities have successfully passed regulatory inspections by the US FDA, EMA, and Health Canada, and are licensed by the Australian TGA for cGMP manufacturing of bulk drug substance and sterile drug product. BioCina has a proven track record of producing high-quality drug products distributed to 98 countries across North America, South America, Europe, Asia, and Africa. BioCina is proud to serve clients from every major market in the global industry, and because BioCina is not a drug developer, its focus is solely on serving its clients’ products. Australia offers one of the most attractive tax incentives available globally (up to 48.5% cash refund), making it an ideal destination for drug developers looking to invest in scaling-up and manufacturing their products. As one of the fastest growing companies in the biopharmaceutical industry across Australia, BioCina was awarded the 2024 South Australia “Emerging Business of the Year” award. Learn more at https://biocina.com. | BioCina is a global, end-to-end contract development and manufacturing organisation (CDMO) headquartered in Australia, serving pharma and biotech clients from early clinical development through to commercial supply. With GMP facilities spanning drug substance biologics and sterile fill-finish drug product, BioCina is the leading end-to-end CDMO in Australia and the Southern Hemisphere — offering clients a single project team and seamless progression from molecule to market. A Heritage Built for Complex Manufacturing BioCina’s GMP facilities carry a combined pharmaceutical heritage of over 50 years, previously part of Pfizer’s global manufacturing network by way of Hospira. Our specialists carry an average tenure of 15 years, delivering industry-leading OTIF performance across clinical and commercial supply, across modalities, and across 100+ countries. Over 600 approved products bear that manufacturing history. Drug Product: The Full Spectrum of Sterile Fill-Finish BioCina operates 10 state-of-the-art filling lines with annual capacity exceeding 225 million units, serving both small molecule and biologics programs across the full range of sterile formats: Blow-Fill-Seal (BFS): Seven dedicated lines producing preservative-free, aseptically filled sterile liquids for ophthalmic, inhalation, irrigation, and injectable applications. Multiformat Injectables (Terminal Sterilisation): High-volume vials and glass bottles for IV medications, hospital generics, and small molecule injectables. Cytotoxic Fill-Finish: A dedicated line under Restricted Access Barrier System (RABS) containment for oncology and high-potency liquid injectables. SA25 Cytiva Robotic Aseptic Isolator: Fully closed, robotic filling for vials, prefilled syringes, and cartridges — highest sterility assurance for biologics, biosimilars, and oxygen-sensitive products. EU Annex 1 compliant. Controlled Substances: Manufacturing licences for scheduled drugs enabling GMP production of opioids, benzodiazepines, stimulants, methadone, and more. Non-Sterile Oral Liquids: Commercial-scale production in PET and HDPE bottles, including paediatric, oncology supportive care, and controlled substance formulations. Drug Substance: From Cell to Bulk BioCina offers fully integrated biologics drug substance development and manufacturing, from upstream through to purified and characterised bulk material. Microbial fermentation is the foundation — over 35 years of expertise, scales from development through to commercial production, with full downstream processing and in-house analytical development, method validation, and stability programs. BioCina also offers fully integrated pDNA, mRNA, and LNP manufacturing at clinical and commercial scale — covering plasmid DNA production, in vitro transcription, mRNA capping and purification, and precision microfluidic LNP encapsulation across mRNA, pDNA, saRNA, proteins, peptides, and small molecule payloads — with direct handoff to fill-finish under one organisation. Regulatory Credentials That Travel With Your Product BioCina’s facilities are registered with and inspection-ready, holding product approvals from the US FDA, EMA, TGA, PMDA (Japan), Health Canada and many other leading regulatory authorities, spanning 100+ countries. Australia as a Strategic Advantage Manufacturing in Australia is a competitive position. The Clinical Trial Notification (CTN) pathway enables first-in-human studies to begin in as little as 30 days from submission. The Australian Government’s R&D Tax Incentive provides eligible companies with a refundable tax offset of up to 43.5% on qualifying development expenditure — meaningfully extending program runway. Australia’s political stability, strong IP framework, and English-language operating environment reduce risk. BioCina’s APAC position also provides practical advantages for clients targeting Korean, Japanese, and Southeast Asian markets.
BiBo Biopharma Inc.
BiBo Biopharma Engineering Co. LTD. (BiBo Pharma) is a Contract Development and Manufacturing Organization (CDMO) focus on biologics. We are one of the few organizations in the world with comprehensive experience of construction and operation experience of large-scale biologics production lines, and committed to setting up new CDMO industry standards with our world-leading PanFlex® -Engineering capacity and integrated management system. We offer full-spectrum and one-stop-shop services from R&D to commercial production for multi-platforms, including microbial fermentation, mammalian cell culture, and gene therapy. BiBo’s 30,000L large-scale manufacturing capability, which is the first in China and the 2nd in the world, can provide our client with state-of-the-art service for commercial production. | BiBo Pharma is a full spectrum CDMO covering the entire CMC lifecycle of biologics. BIB has multiple technology platforms, including microbial fermentation, mammalian cell culture, ADC & GMP facility engineering service. Empowered by PanFlex®-Engineering, our specialist team innovated the world’s first and largest 50,000L and 30,000 L stainless steel ultra-large bioreactor for mammalian cell culture production, and 50,000L and 30,000L high cooling capacity fermenters enabling ultra-high-cell-density fermentation. We have bioreactors and fermenters ranging from 50L to 50,000L and can provide high quality, on time drug supply for GLP tox studies through clinical trials and commercial supply. BiBo’s core team members come from world-leading companies in the US, Europe, and China. We have accomplished over 100 biologics projects, including over 30 in clinical and commercial stages. Our CMC service package includes cell line and strain development, process development, analytical development, formulation development, toxicological and GMP production of drug substance and drug product, process characterization, and large-scale production. We are the world leader in the fourth wave of biomanufacturing. Not only have we established the world’s first and largest 50,000L ultra-large mammalian production line, but it has also achieved a 100% success rate on all scale-up projects by applying our innovative “success on the first time” system.
Avid Bioservices, Inc.
Avid Bioservices (NASDAQ: CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology, biopharmaceutical, and cell & gene therapy industries. With over 30 years of experience producing biologics, Avid’s services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.comwww.avidbio.com | Avid Bioservices, a dedicated biologics CDMO, is transforming the CDMO experience. From concept to market, we are your advocate. We have more than 30 years of unrivaled expertise manufacturing biologics and a leadership team with a 10-year average operational leadership tenure. Our world-class mammalian protein facilities are located in Orange County, CA. We’ve produced more than 250 commercial batches, and 5 commercial products marketed in 90+ countries. We maintain the highest level of compliance with a dedication to continuously improving our quality systems and manufacturing processes. For more than 10 years, we’ve maintained a flawless quality track record which we’re committed to uphold. From early-stage to late-stage, concept to market, every part of our process is personalized. We’re your advocates, your trusted experts, your true partners. For more information, visit AvidBio.com. | Avid Bioservices, a dedicated biologics CDMO, is transforming the CDMO experience. From concept to market, we are your advocate. We have more than 30 years of unrivaled expertise manufacturing biologics and a leadership team with a 10-year average operational leadership tenure. Our world-class mammalian protein facilities are located in Orange County, CA. We’ve produced more than 250 commercial batches, and 5 commercial products marketed in 90+ countries. We maintain the highest level of compliance with a dedication to continuously improving our quality systems and manufacturing processes. For more than 10 years, we’ve maintained a flawless quality track record which we’re committed to uphold. From early-stage to late-stage, concept to market, every part of our process is personalized. We’re your advocates, your trusted experts, your true partners.
Asymchem
Founded in 1999, Asymchem is a global integrated Contract Development and Manufacturing Organization (CDMO) providing drug R&D and manufacturing for leading pharmaceutical and biotech companies. Our mission is to drive smarter, greener and more cost-effective manufacturing to support clinical research and commercialization. Asymchem currently operates eight manufacturing facilities offering solutions ranging from early clinical stage to commercial stage, including R&D, cGMP production of advanced intermediates, APIs, formulations and clinical research services. Our scientists excel in the creation and manufacture of enzymes for use in bio-catalysis, the development of practical continuous flow technologies for commercialization, and innovative research and process development from preclinical research to commercialization for both non-GMP or GMP products. Our work has frequently won us “most valuable partner” and “strategic partner” recognition from major pharma and leading biotech companies. For more information, please visit www.asymchem.com. | Asymchem is a leading global CDMO known for its integrated offerings throughout the entire drug development lifecycle. From early-stage research to commercialization, we provide a tailored suite of services that cater to the specific needs of each project. We are committed to embracing cutting-edge technologies that not only enhance efficiency and safety but also prioritize sustainability in the development and manufacturing process. This translates to smarter, greener, and more cost-effective solutions for our clients, ultimately speeding up the delivery of life-saving medications to patients. | Asymchem (Stock Code: 002821.SZ/6821.HK), a global CDMO leader, has provided one-stop pharmaceutical solutions for over 25 years. With a strong foundation in small molecule services, it has advanced capabilities in TIDES, biologics, drug products, clinical research, synthetic biology, and technology transfer. Supported by over 9,000 professionals—45% in R&D—and facilities in China, the U.S., the U.K., and beyond, Asymchem adheres to top-tier cGMP and EHS standards. Trusted by global pharma and biotech leaders, Asymchem delivers high-quality, cost-effective services, reducing time-to-market for therapies and providing client-centric solutions to meet the diverse needs of global drug development.
ARx
ARx leverages over 60 years of expertise in film and adhesive polymer science to develop transdermal, oral, buccal, and sublingual thin films. These films enhance drug release, absorption, and bioavailability, advance pharmacokinetics, and improve patient safety and experience. A pioneer in novel dosing strategies, ARx partners closely with clients to push the boundaries of drug delivery, offering end-to-end solutions from feasibility through FDA-registered manufacturing. With demonstrated success in commercializing branded and generic drug products and by setting higher standards for quality, safety, and efficacy, ARx continues to expand therapeutic potential and redefine what’s possible in modern medicine.
Ardena
Ardena is as a fully integrated Contract Development and Manufacturing Organization (CDMO), with a core focus on bringing molecules to the clinics. Our comprehensive suite of services caters to every stage of pharmaceutical development, ensuring a smooth progression from initial idea to clinical application. From small-molecule API projects, to drug product development, navigating phase-appropriate processes under cGMP conditions, and facilitating clinical packaging and logistics. Furthermore, as experts in nanomedicine development, we offer scalable formulation, process, and analytical development, alongside GMP manufacturing, ensuring our partners meet their clinical schedules effectively. Ardena is also recognized for its expertise in bioanalysis solutions that cater to diverse drug products and biomarkers, spanning small molecules to proteins, including antibodies, ADCs, oligonucleotides, and vaccines. As your trusted CDMO partner connect with our team at the California Pavilion and let us assist you on your journey towards clinical success. | Ardena is a specialist CDMO and bioanalytical CRO advancing precision medicines and other complex therapies from early development through to commercial supply. The company supports biotech and pharmaceutical partners in translating challenging molecules into scalable, robust therapies. Its strength lies in combining complex drug product development and GMP manufacturing, bioanalytical services, and specialized expertise in nanomedicine and conjugates within one integrated framework. This approach reduces complexity, shortens timelines, and supports efficient progression across development stages. Ardena focuses on modalities that demand advanced formulation and analytical precision, including nanoparticles, conjugates, and other complex drug products. In nanomedicine, the company supports lipid-based, polymer-based, and metal-based systems, optimizing formulation, scalability, and manufacturability. Drug product capabilities span formulation development, process scale-up, and GMP manufacturing for clinical and commercial supply. Enabling technologies such as spray drying and hot melt extrusion address solubility, stability, and bioavailability challenges, alongside expertise in highly potent and complex dosage forms. Ardena also supports the development of conjugates, including antibody-drug conjugates (ADCs) and other novel conjugates (XDCs). These programs require tight integration of chemistry, formulation, and analytics, combined with containment and GMP expertise to ensure consistency from early development through to commercial manufacturing. Bioanalytical services are a central pillar, delivering pharmacokinetic, biomarker, and immunogenicity analysis to support clinical development and regulatory submissions. Ardena operates established bioanalytical laboratories in Europe and has expanded into the United States with a new lab in Somerset. Ardena’s international network spans Europe and the US, enabling regional flexibility and continuity from development to commercialization. The Somerset site plays a key role, offering GMP drug product manufacturing for clinical and commercial supply, alongside integrated bioanalytical capabilities. As an FDA-approved facility, it provides a strong foundation for programs targeting the US market, with clear advantages in supply chain efficiency and market access. What differentiates Ardena is the integration of its expertise. Multidisciplinary teams align development, manufacturing, and analysis from the outset, reducing rework and supporting consistent execution. Supporting capabilities in solid-state research and CMC development further strengthen programs and de-risk critical decisions. At this event, Ardena brings practical insight across the full development lifecycle, supporting focused discussions on how to advance complex therapies with speed, control, and confidence. Visit Ardena at booth 3253. Ardena enables progress where complexity defines the challenge.
ARCALIS
ARCALIS leads the world as the most advanced CDMO for mRNA vaccines and therapeutics. ARCALIS is a contract development and manufacturing organization (“CDMO”) for messenger RNA (mRNA) vaccines and therapeutics. The company was jointly established by Axcelead, Inc., the first drug discovery platform company in Japan, and Arcturus Therapeutics, a US-based, global, late-stage clinical mRNA medicines company. mRNA is a new therapeutic and vaccine modality that was only recently commercialized in the wake of the Coronavirus infection, but the challenge toward practical application has been ongoing since the 1990s. Research and development of mRNA have begun targeting not only infectious diseases, but also therapeutics and vaccines for various applications, such as rare diseases, cancer, regenerative medicine, and genome editing.The company provides drug discovery support, CMC development, and manufacturing support services for mRNA therapeutics and vaccines to pharmaceutical and biotech companies. These services are backed by expertise accumulated in Arcturus in the fields of manufacturing technologies.
Andelyn Biosciences
Our Vision: Pioneering Solutions that turn Hope into Reality Our Mission: Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions that turn hope into reality as a cell and gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. Having 20+ years of experience with viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting/characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 400+ cGMP clinical batches, Andelyn provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing, full quality system/regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility will expand capacity across 8+ production suites for customization of new programs and tech transferred programs, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Gene and cell therapy, AAV viral vector manufacturing, Plasmid Manufacturing, Lentiviral vector Manufacturing, Commercial Manufacturing, CDMO, analytical method development, GMP, fill finish, QC/QA release testing, Process Characterization, Regulatory Affairs, Licensing Andelyn Biosciences is a pioneering cell and gene therapy organization born out of Nationwide Children’s Hospital, where the first FDA-approved systemic gene therapy was discovered. See all our Press Releases at: https://www.andelynbio.com/media-center | Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions for Turning Hope into Reality (TM) as a gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. With 20+ years of experience in viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting and characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 450+ cGMP sublots, Andelyn provides research, tox, and GMP grade plasmids Andelyn also has full quality and regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility offers capacity across 16 production suites for customization of new programs as well as tech transfer programs, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Andelyn Biosciences is a pioneering gene therapy CDMO born out of Nationwide Children’s Hospital, where the first FDA-approved systemic gene therapy was discovered. | Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn’s deep scientific expertise has resulted in the production of cGMP material for more than 450 clinical batches and 75 global clinical trials. Operating out of its development and manufacturing facilities in Columbus, Ohio, Andelyn supports its clients in developing cell and gene therapies from concept through plasmid engineering and manufacturing, process and analytical development, and cGMP clinical and commercial manufacturing. Andelyn can accelerate programs and deliver high quality products by developing and manufacturing processes on its configurable, data-driven AAV CuratorTM Platform, or tech transferring in an established client program. Capabilities include cGMP manufacturing for suspension processes up to a 2,000-liter and adherent processes. A rigorous quality system, regulatory support, and supply chain vertical integration further support clients in bringing their critical therapies to market. For more information, visit andelynbio.com. For Andelyn media inquiries, please contact: media@andelynbiosciences.com
Almac Group
Almac Diagnostic Services We are a precision medicine company specialising in biomarker driven clinical trials. Our global CLIA and CAP accredited laboratories cover UK, Europe, USA and APAC regions. Our cores services: * Multi-Omic Services: We offer a range of genomic & proteomic platform and chemistry options, alongside expert data sciences support & a specialty central lab service. * Clinical Biomarker & CDx Development: Custom Clinical Biomarker & CDx development, validation & delivery service from our CLIA & CAP accredited laboratories in USA, Europe and APAC. * Clinical Testing: Global clinical trial testing service from our clinical laboratories, including a menu of platforms & assays and an integrated specimen collection & logistics service. Find Out More www.almacgroup.com/diagnostics | The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Operating from state-of-the-art facilities in the US, Europe, and the UK, Almac Pharma Services is a FDA, HPRA, and MHRA approved CDMO partnering with global pharmaceutical and biotechnology industries. We have over 50 years’ experience in providing a comprehensive range of tailored solutions. Almac possesses a wealth of technical expertise to support the delivery of your complex projects. Our scientists can develop your clinical candidate into an optimum formulation, and solid manufacture oral dose products for all stages of clinical trials. Almac’s integrated pharmaceutical development solutions are tailored to meet your needs. We specialise in the manufacture & primary packaging of solid, oral dosage forms (Tablets, Capsules and Powders). As well as customised secondary packaging for all drug products including ultra-low temperature drug products. Almac works in close partnership with our clients offering unique solutions designed to support the efficient and successful development, and commercialisation of new treatment options. | Operating from state-of-the-art facilities in the US, Europe, and the UK, Almac Pharma Services is a FDA, HPRA, and MHRA approved CDMO partnering with global pharmaceutical and biotechnology industries. We have over 50 years’ experience in providing a comprehensive range of tailored solutions. Providing end-to-end integrated solutions to bring your drug product from development through to commercialisation from a single source. We work with clients to provide pharmaceutical development, manufacturing, product launch, and packaging solutions to fit their unique needs. Our team of experts can support the development of fit-for-purpose formulation for First-in-Human trials, to developing a more robust formulations scaling up for late phase trials, and ultimately commercialisation. Supporting key development and manufacture areas such as paediatrics, potent and highly potent products. We provide primary and secondary packaging for all drug products including ultra-low temperature drug products and specialised kit assembly. Almac was one of the 1st EU CDMOs to support gene therapy product launches, and currently supports 25% of EU approved/pre-registration Gene Therapy solutions. We provide end-to-end management of drug product supply, including distribution, packaging design, and support initial and ongoing global product launch. We provide unique, tailormade solutions designed to support the efficient and successful development, and commercialisation of new treatment options. Partnering with our clients to provide flexible, stable, ongoing supply to meet their product pipeline needs. | The Almac Group is a global leader in providing a range of expert services and support across the drug development lifecycle. A privately owned organisation, under the McClay Foundation, Almac has grown organically over the past five decades, now employing over 7,500 highly skilled individuals across 18 locations in Europe, the US and Asia. Almac Group is comprised of 5 Business Units: • Almac Diagnostic Services • Almac Sciences • Almac Pharma Services • Almac Clinical Services • Almac Clinical Technologies Each Business Unit offers specialist and dedicated solutions at each phase of the product lifecycle providing the ability to select single or multiple, integrated solutions to meet your unique needs. Our unique combination of inspirational people, exceptional innovation and outstanding quality, enables us to provide tailored solutions for your specific requirements – either on a single, standalone project or on a long-term basis as your strategic partner. About Almac Pharma Services: With over 55 years’ experience, Almac Pharma Services is an established, reliable and world leading outsourcing partner to the global pharmaceutical and biotechnology industry. Employing over 1,800 highly skilled individuals across 4 locations in Europe and the US, we provide a range of tailored, quality-led and timely solutions from early and late phase pharmaceutical development, clinical and commercial drug product manufacture, product launch through to commercial packaging and global distribution. Currently supporting client portfolios across more than 70 countries, our fully integrated, end-to-end solutions are tailored to meet the needs of your unique products, and, ultimately, your patients. Pharmaceutical Development Solutions: Spanning both early and late phase development, our teams of expert scientists possess a wealth of experience in developing clinical candidates into optimal formulations and manufacturing high-quality oral dose products for all phases of clinical trials. Operating both non-GMP and GMP facilities we have complementary equipment trains and integrated technical teams to facilitate technology transfer providing a seamless transition between formulation and process development, and clinical trial material manufacturing. Through a range of flexible and fully tailored unit operations including blending, roller compaction, high shear granulation, encapsulation (including Xcelodose) micro encapsulation and fluid bed processing, we offer the following oral dose formulations with batch sizes ranging from grams to tons: • API / powder in hard gelatin capsules or bottles, including micro-dosing • Formulated blends in hard gelatin capsules or bottles • Tablets (coated) • Mini-tablets • Granules • Beads/pellets • Non-sterile liquid in capsules or bottles • Immediate and modified release • Fixed dose combination products • Potent and highly potent products (OEL as low as 0.05 ug/m3/8 hours) • Specialist paediatric drug development expertise Analytical Solutions: We employ over 700 highly skilled analysts working in state-of-the-art, fully certified GMP laboratories across Europe and the US with significant experience in the analysis of both small and large molecules. We support drug substance (API) and drug product (finished product) analytics across all phases of clinical development through to commercial release. We offer a range of tailored services including: • Method development • Method validation • Method transfer • Stability programmes • Release analysis: all lifecycle stages • Spectroscopy services • Investigational analysis • Reference standard management • Microbiological testing • Physical sciences • Bio-pharmaceutical testing • Analytical support for clinical trial supplies Commercial Manufacture Solutions: Scaling up from our oral dose development assets and expertise through registration and launch into commercial supply, or transferring existing commercial products, we support your commercial manufacturing needs with flexibility and expertise. With blend sizes from 10kgs up to 2.5 tons, our range of state-of-the-art processing equipment is designed to enable scalability to the batch size requirements of your product for a range of presentations including: • Tablets • Mini-tablets • Capsules • Powders • Granules • Beads/pellets • Non-sterile liquids • Potent and highly potent products (OEL as low as 0.05 ug/m3/8 hours) • Specialist paediatric drug manufacturing expertise Commercial Packaging Solutions: Our high and low throughput operations provide the flexibility and efficiency necessary to meet your ongoing and fluctuating demand. Our commercial facilities in Europe and the US, combined with our local expertise offers flexible, quality-led commercial pharmaceutical packaging solutions tailored to meet your specific needs. Our range of primary packaging solutions include: • Tablets • Mini-tablets • Capsules • Powders • Granules • Non-sterile liquid • Our secondary packaging, labelling and assembly capabilities include: • Bottles Vials / ampoules • Pre-filled syringes • Wallets / blister cards • Auto-injectors • Cartons • Sachets • Stick packs • Offline blister printing Innovative, specialist packaging solutions including: • Specialist paediatric drug packaging expertise • Expert cell and gene therapy (ATMP) Ultra Low Temperature (ULT) solutions (-20° to -80°) • Complex medical kit assembly solutions via our unique, custom built semi-automated packaging technology Support Solutions: We provide a wide range of tailored support and consultancy services to help guide you through every aspect of your unique development and commercialisation journey. Find out more – www.almacgroup.com
Allsino Pharmaceutical Co., Ltd.
Allsino pharmaceutical Co., Ltd. Your Premier Partner in Small Molecule & Peptide CDMO Services Company Overview Founded in May 2004, Allsino Biopharmaceutical Co., Ltd.is a wholly-owned subsidiary of Sinopep-Allsino Biopharmaceutical Co., Ltd. (Stock Code: 688076), a publicly traded company on the Shanghai Stock Exchange’s STAR Market . Headquartered in Hangzhou, China, Allsino is a globally recognized Contract Development and Manufacturing Organization (CDMO), specializing in the research, development, and production of innovative small molecule drugs, advanced pharmaceutical intermediates, and peptide fragments. With a steadfast commitment to quality and innovation, Allsino serves as a critical bridge between early-stage drug discovery and commercial manufacturing, helping partners accelerate timelines and reduce risks. Strategic Locations: R&D and GMP Manufacturing Allsino operates an integrated Hangzhou R&D + Jiande Manufacturing” dual-site model to ensure seamless technology transfer and scalable production. R&D Center (Hangzhou, Zhejiang): Location: Yuhang District, Hangzhou. Status: Recognized as a Provincial Enterprise Research Institute by the Zhejiang Provincial Government . Capabilities: Houses over 100 scientists, including Ph.D. and Master’s level chemists. The center focuses on core technologies such as small molecule catalysis, continuous flow chemistry, and solid-phase peptide synthesis. – GMP Commercial Production Base (Jiande, Zhejiang): – Location:Jiande City, Hangzhou. – Scale: Spanning 60,000+ square meters(approx. 146 Mu) . – Certification: Operates under strict cGMP standards, compliant with US FDA, EDQM, and NMPA regulations . In 2023, the facility successfully passed the NMPA GMP evaluation for APIs . Core Business & Technical Expertise Allsino is an innovation-driven entity that has successfully initiated and developed over 300 projects across various therapeutic areas, including oncology, central nervous system (CNS) disorders, and metabolic diseases (including GLP-1 analogs for diabetes and obesity) . Key Services: Process Development & Scale-up: From laboratory synthesis to multi-ton commercial production. – Custom Synthesis: Advanced intermediates, Registered Starting Materials (RSMs), and GMP-grade Active Pharmaceutical Ingredients (APIs) . Peptide CDMO Services:Specializing in peptide fragments and oligonucleotides. Commercial Manufacturing: Supporting NDA filings and commercial launch. Quality & Global Recognition Allsino’s commitment to pharmaceutical excellence is validated by its long-standing partnerships with top-tier global pharmaceutical companies. Global Partnerships:The company has established long-term technical collaborations with Fortune 500 pharmaceutical companies such as ****** . Industry Award: In 2022, Allsino was honored with the “SK Pharmteco Preferred Partner Award” at CPhI Frankfurt. Notably, Allsino was the only Chinese company selected among nearly 100 global suppliers to receive this distinction . Intellectual Property: Holds over 20 patents (including inventions and utility models) . Certifications – US FDA (cGMP) – NMPA (China GMP) – ISO 9001, ISO 14001, ISO 45001 Workforce & Assets Employees:500+ , including a highly educated technical team of 240+ professionals (6 Ph.D.s, 16 Master’s degrees) . Annual R&D Investment: Consistently exceeds 10% of revenue, ensuring continuous technological innovation . Contact Information Website:[www.allsino.com](http://www.allsino.com) R&D Center Address: 4F, Building 1, No. 39 Keji Avenue, Yuhang District, Hangzhou, Zhejiang, China (Postal Code: 311121) Manufacturing Base Address:No. 18 Fenghe Road, Xiaya Town, Jiande City, Hangzhou, Zhejiang, China (Postal Code: 311606) Phone: +86-571-89961929 / +86-571-88180350 Email (Sales): sales@allsino.com Allsino pharmaceutical Co., Ltd.—Bridging Innovation from Lab to Market.